Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers.
Nuclera has raised $12.0M in total funding. The most recent round was Series C. The last funding was announced in January 2026.
Nuclera's investors include British Business Bank, Patient Square Capital, Amadeus Capital Partners, Verve Ventures, Cambridge Innovation Capital.
Nuclera is headquartered in Cambridge, United Kingdom.
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers.
Nuclera is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuclera — Funding & Investors." VCBacked, January 13, 2026, https://www.vcbacked.co/company/nuclera. Accessed September 16, 2026.
VCBacked. (2026). Nuclera — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/nuclera
{{cite web |title=Nuclera — Funding & Investors |url=https://www.vcbacked.co/company/nuclera |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated